Division of Nephrology and Hypertension and Departments of.
Radiology and.
Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1151-1160. doi: 10.2215/CJN.14691218. Epub 2019 Jul 30.
Intracranial aneurysm rupture is the most devastating complication of autosomal dominant polycystic kidney disease. Whether selective or widespread intracranial aneurysm screening is indicated remains controversial.
DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: Records of 3010 patients with autosomal dominant polycystic kidney disease evaluated at the Mayo Clinic between 1989 and 2017 were reviewed. Those who had presymptomatic magnetic resonance angiography screening were included.
Ninety-four intracranial aneurysms were diagnosed in 75 of 812 (9%) patients who underwent magnetic resonance angiography screening. Sex, age, race, and genotype were similar in the groups with and without aneurysms; hypertension and history of smoking were more frequent in the aneurysm group. Twenty-nine percent of patients with aneurysms compared with 11% of those without aneurysms had a family history of subarachnoid hemorrhage (<0.001). Most aneurysms were small (median diameter =4 mm; range, 2-12 mm); 85% were in the anterior circulation. During a total imaging follow-up of 469 patient-years, intracranial aneurysms were detected in five patients; eight intracranial aneurysms grew (median =2 mm; range, 1-3 mm). During a total clinical follow-up of 668 patient-years, seven patients had preemptive clipping or coil embolization; no intracranial aneurysms ruptured. During a total clinical follow-up of 4783 patient-years in 737 patients with no intracranial aneurysm detected on the first magnetic resonance angiography screening, two patients had an intracranial aneurysm rupture (0.04 per 100 person-years; 95% confidence interval, 0 to 0.10). The rate of intracranial aneurysm rupture in large clinical trials of autosomal dominant polycystic kidney disease was 0.04 per 100 patient-years (95% confidence interval, 0.01 to 0.06).
Intracranial aneurysms were detected by presymptomatic screening in 9% of patients with autosomal dominant polycystic kidney disease, more frequently in those with familial history of subarachnoid hemorrhage, hypertension, or smoking. None of the patients with and two of the patients without aneurysm detection on screening suffered aneurysmal ruptures. The overall rupture rate in our autosomal dominant polycystic kidney disease cohort was approximately five times higher than that in the general population.
颅内动脉瘤破裂是常染色体显性多囊肾病最具破坏性的并发症。是否需要进行选择性或广泛的颅内动脉瘤筛查仍存在争议。
设计、地点、参与者和测量方法:回顾了 1989 年至 2017 年间在梅奥诊所接受评估的 3010 例常染色体显性多囊肾病患者的记录。纳入了接受无症状性磁共振血管造影筛查的患者。
在接受磁共振血管造影筛查的 812 例患者中的 75 例(9%)中诊断出 94 个颅内动脉瘤。有和无动脉瘤的患者在性别、年龄、种族和基因型方面相似;动脉瘤组中高血压和吸烟史更为常见。有动脉瘤的患者中有 29%(94/322)有蛛网膜下腔出血家族史,而无动脉瘤的患者中有 11%(39/358)有蛛网膜下腔出血家族史(<0.001)。大多数动脉瘤较小(中位数直径=4mm;范围,2-12mm);85%位于前循环。在 469 患者年的总影像学随访期间,有 5 例患者发现颅内动脉瘤;8 个颅内动脉瘤增大(中位数=2mm;范围,1-3mm)。在 668 患者年的总临床随访期间,有 7 例患者进行了预防性夹闭或线圈栓塞;无颅内动脉瘤破裂。在首次磁共振血管造影筛查未发现颅内动脉瘤的 737 例患者中,有 4783 患者年的总临床随访期间,有 2 例患者发生颅内动脉瘤破裂(0.04/100 患者年;95%置信区间,0-0.10)。常染色体显性多囊肾病大型临床试验的颅内动脉瘤破裂率为 0.04/100 患者年(95%置信区间,0.01-0.06)。
常染色体显性多囊肾病患者通过无症状性筛查发现颅内动脉瘤,在有蛛网膜下腔出血、高血压或吸烟家族史的患者中更为常见。在有和无动脉瘤检测的患者中均未发生动脉瘤破裂。我们的常染色体显性多囊肾病患者队列的总体破裂率约为普通人群的五倍。